Themis Medicare Limited (BOM:530199)
India · Delayed Price · Currency is INR | Market Cap | 9.39B -24.6% |
| Revenue (ttm) | 3.42B -15.6% |
| Net Income | 11.44M -96.2% |
| EPS | 0.12 -96.3% |
| Shares Out | 92.10M |
| PE Ratio | 821.24 |
| Forward PE | n/a |
| Dividend | 0.50 (0.49%) |
| Ex-Dividend Date | Sep 4, 2025 |
| Volume | 2,463 |
| Open | 102.00 |
| Previous Close | 102.20 |
| Day's Range | 101.10 - 103.40 |
| 52-Week Range | 65.00 - 147.99 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | May 28, 2026 |
About Themis Medicare
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolyti... [Read more]
Financial Performance
In fiscal year 2026, Themis Medicare's revenue was 3.42 billion, a decrease of -15.60% compared to the previous year's 4.06 billion. Earnings were 11.44 million, a decrease of -96.17%.
Financial StatementsNews
Themis Medicare shares surge nearly 2% following amalgamation announcement
Shares of Themis Medicare climbed 1.15% to ₹289.20 on the NSE as of 9:53 AM after the company announced its decision to merge Gujarat Themis Biosyn Limited (GTBL) with Themis Medicare Limited (TML). T...